Background {#Sec1}
==========

Chronic kidney disease (CKD) is fast becoming a leading public health issue in Africa, with an estimated prevalence of 14.3% in the general population, and 36.1% in high-risk populations \[[@CR1]\]. Due in part to increasing rates of type 2 diabetes, hypertension and obesity, the prevalence of CKD continues to rise \[[@CR2]\]. However, marked variability in the incidence of CKD between population groups, suggests additional factors contributing to CKD aetiology \[[@CR3]\]. Indeed, prevalent end-stage renal disease (ESRD), which is the terminal stage of CKD, is 4-fold higher among African ethnicity as compared to European ethnicity \[[@CR4], [@CR5]\] and individuals of African ethnicity progress faster from moderately decreased kidney function to ESRD \[[@CR6]\]; thus highlighting African ethnicity as a contributing risk factor for CKD \[[@CR4], [@CR5]\].

Over the past decade, through the use of genome-wide association studies (GWAS), researchers have identified various genomic regions with common genetic variants associated with CKD traits \[[@CR7]\]. However, a limitation of the majority of GWAS's conducted to date is the paucity of studies conducted in individuals of African ancestry and even less in Africans living in Africa \[[@CR7]--[@CR10]\]. Despite, Africa being one of the most ethnically and genetically diverse regions of the world \[[@CR11]\], these populations are understudied, with most of the common loci associated with CKD in non-African populations not being replicated in African populations. Though African migrants living in Europe and America are genetically linked with African ancestry \[[@CR12], [@CR13]\], these genetic variants cannot be extrapolated to Africans residing in Africa. This is mainly due to genetic admixture of American and European populations, as well as differences in environment, cultural and lifestyles \[[@CR11]\]. Accordingly, identification of genetic loci for CKD in African populations will help to advance our understanding of the underpinnings of CKD in individuals of African descent.

There is currently no systematic review evaluating the CKD-associated genes found in African populations residing in Africa. The main purpose of this review is thus to critically evaluate the existing studies on CKD genetic risk inferred by polymorphisms amongst African populations in Africa, and explore the specific effect these genetic loci have on CKD development in the African population.

Methods {#Sec2}
=======

Protocol and registration {#Sec3}
-------------------------

The review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis PRISMA framework \[[@CR14]\] and HuGENET™ HuGE Review handbook \[[@CR15]\]. The methods of the analysis and inclusion criteria were specified in advance and documented in a protocol in the PROSPERO database (registration number: CRD42017058440).

Selection of eligible studies, types of studies and sources of information {#Sec4}
--------------------------------------------------------------------------

Relevant studies published until August 2017 were identified through a comprehensive electronic search of major databases such as MEDLINE (via PubMed)*,* EBSCOhost, Scopus, and Web of Science, using an African search filter \[[@CR16]\] and without any starting date or language restrictions. Medical Subject Headings (MeSH) terms and Boolean operators, such as AND/OR/NOT, were used to string terms together (refer to Additional files [1](#MOESM1){ref-type="media"}, [2](#MOESM2){ref-type="media"}, [3](#MOESM3){ref-type="media"} and [4](#MOESM4){ref-type="media"}: Tables S1--S4). Publication bibliographies were searched to further enhance the search strategy.

Data collection {#Sec5}
---------------

Two authors (CG and YYY) independently conducted the database searches and sequentially (titles, abstracts and then full texts) screened them for inclusion (Fig. [1](#Fig1){ref-type="fig"}). In situations of disagreements between the two authors, a third author (APK) arbitrated for eligibility. The inclusion criteria was that a study had to be an original study containing independent data that were obtained from case-control or cohort studies, which specifically conducted genetic association analyses on African populations residing in Africa. These studies had to report on study population characteristics, methods, CKD or renal traits (such as serum creatinine, estimated glomerular filtration rate (eGFR), urinary albumin excretion), genes and polymorphisms, genotyping technique(s), statistical analyses, and report on allele and genotype frequencies. Studies were excluded if, \[[@CR1]\] the conducted analyses were exclusively on migrant African populations, \[[@CR2]\] the entire cohort consisted of only high-risk individuals (a population of only type 2 diabetic or hypertensive patients), \[[@CR3]\] the study did not report the estimate effects and/or *p*-values, allele and genotype frequencies, and if \[[@CR4]\] the study was a meta-analysis, review or any other form of publication that do not have primary data. Full articles were obtained for all abstracts and titles that met inclusion criteria as well as those that certainty of inclusion was unclear. The two authors (CG and YYY) screened the full-text articles, and selected full manuscripts according to the inclusion criteria. Disagreements were resolved through discussion or if consensus were not met, reviewed by a third author (APK). The reasons for excluding studies were also recorded.Fig. 1Selection process for studies included in the systematic review

Data extraction, assessment and synthesis {#Sec6}
-----------------------------------------

The data extracted from selected articles included the name of the first author and year of publication, study setting and design, population characteristics, genetic models used for measures of association, adjustment (if any) for confounding variables, allele and genotype frequencies, and the study outcome. Data extraction was done by one author (CG), and another author (YYY) verified the accuracy and validity of extracted data. As recommended by Sagoo et al. \[[@CR17]\], we assessed the existence of bias considering the following: case definition, population stratification, reporting of methods used (sample size of a study population, genotyping method and its reliability/accuracy, validation of results, statistical analyses). Given the very few studies investigating the effects of the same SNPs on CKD risk across different settings/countries, attempting to pool studies were deemed meaningless, thus, we opted to conduct a narrative synthesis of the evidence instead of a meta-analysis.

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

We retrieved 2787 citations (962 from EBSCOhost; 754 from MEDLINE; 568 from SCOPUS; 501 from Web of Science; 2 from publication bibliography) from our searches. Of these, 2771 citations were not eligible for inclusion for the following reasons: duplicate (*n* = 1567) or irrelevant to this review based on the title or abstract (*n* = 1204). Consequently, 16 full-text articles were reviewed and of those, three citations were excluded, based on not meeting the inclusion criteria of this review, resulting in 13 eligible articles retained for the systematic review (Fig. [1](#Fig1){ref-type="fig"}).

Characteristics of included studies {#Sec9}
-----------------------------------

Table [1](#Tab1){ref-type="table"} describes the characteristics of the genetic studies included in this review. All the studies were conducted between 2009 and 2016 with the vast majority conducted in Egypt (*n* = 7), followed by Nigeria and South Africa (*n* = 2, each), and Morocco and Tunisia each with only one reported study on CKD genetic association. Overall, nine studies (69.2%) were from three north-African countries \[[@CR18]--[@CR26]\] and the rest from sub-Saharan African countries \[[@CR27]--[@CR30]\]. The study population ranged from 87 to 859 participants per study, with the mean age ranging from 8.7 to 58.9 years and a male predominance in all except the two South African studies, where only 22--23% were male \[[@CR27], [@CR28]\]. Of the thirteen studies included, kidney dysfunction was characterized mainly by an estimated glomerular filtration rate (eGFR) equal to or less than 60 ml/min/1.73m^2^ \[[@CR18], [@CR23], [@CR25], [@CR27], [@CR28]\]. The remaining studies used other surrogate measures to determine kidney dysfunction, which included ESRD (undergoing haemodialysis) \[[@CR19], [@CR21], [@CR22], [@CR24], [@CR26]\], elevated serum creatinine levels \[[@CR20]\] and a combination of serum creatinine levels greater or equal to 170 μmol/l and dipstick proteinuria greater or equal to 2 \[[@CR30]\] or serum creatinine above 1.4 mg/dl (men) and 1.2 mg/dl (women) and urinary albumin to creatinine ratio (ACR) above 30 mg/g \[[@CR29]\]. The CKD patients included in these studies were of different aetiologies, reflective of the diversity in nephropathy present in Africa.Table 1Characteristics of genetic studies conducted in AfricaAuthorsStudy designCountryPopulationSample size (case/control)Mean age (years±SD)Male (%) (case/control)Measure of kidney dysfunctionType of nephropathyTayo et al. \[[@CR29]\]Case-controlNigeriaYoruba tribe87/7942.1 ± 16.9 (case)\
35.2 ± 8.2 (control)53/51*Serum creatinine* (\> 1.4 mg/dl, men; \> 1.2 mg/dl, women) *Spot urine* (ACR \> 30 mg/g)Hypertension-associated (50.5%)\
HIV-associated (9.2%)\
Proteinuric (40.2%)Ulasi et al. \[[@CR30]\]Case-controlNigeriaIgbo tribe44/4346.6 ± 17.8 (case)\
42.7 ± 10.9 (control)57/63Serum creatinine (≥170 μmol/l or proteinuria ≥2+)HIV-associated (18.2%)\
NS (81.8%)Matsha et al. \[[@CR28]\]Cross-sectionalSouth AfricaMixed-race*By MDRD*\
68/648\
*By CKD-EPI*\
67/64953.6 ± 14.9 (total)22.1 (total)eGFR (\< 60 ml/min/1.73m^2^ based on MDRD and CKD-EPI equations)NSMatsha et al. \[[@CR27]\]Cross-sectionalSouth AfricaMixed-race*By MDRD*\
79/780\
*By CKD-EPI*\
73/78653.1 ± 14.1 (total)22.7 (total)eGFR (\< 60 ml/min/1.73m^2^ based on MDRD and CKD-EPI equations)NSLahrach et al. \[[@CR21]\]Case-controlMoroccoNS109/9744.9 ± 14.4 (case)\
46.8 ± 11.8 (control)NSESRD undergoing haemodialysisNSHanna et al. \[[@CR19]\]Case-controlEgyptNS50/4437.9 ± 14.3 (case)\
NS (control)64/NSESRD undergoing haemodialysisDiabetic nephropathy (26%)\
Hypertensive nephrosclerosis (22%)\
Systemic lupus erythematosus (8%)\
Polycystic kidney disease (10%)\
Idiopathic (34%)Kerkeni et al. \[[@CR20]\]Case-controlTunisiaNS100/12051.0 ± 15.0 (case)\
54.0 ± 10.0 (control)55/73Serum creatinine (thresholds NS; groups included MRF, SRF and ESRD)Non-diabetes CKD with the following aetiologies: Chronic glomerular nephritis (41%)\
Chronic tubulointerstitial nephropathy (30%)\
Vascular nephropathy (23%)\
Idiopathic (6%)Elshamaa et al. \[[@CR18]\]Case-controlEgyptNS78/309.14 ± 7.59 (CT); 10.62 ± 3.49 (MHD) (case)\
8.7 ± 4.51 (control)51/67eGFR (according to K/DOQ1 guidelines):\
*Undergoing CT* GFR (range, 15--29 ml/min/1.73m^2^) *Undergoing MHD* GFR (range, 5--15 ml/min/1.73m^2^)Advanced CKD with the following aetiology:\
Renal hypoplasia/dysplasia (20.5%)\
Obstructive uropathies (17.9%)\
Neurogenic bladder (7.7%)\
Metabolic (2.6%)\
Hereditary nephropathies (21.8%)\
Glomerulopathy (2.6%)\
Idiopathic (26.9%)Radwan et al. \[[@CR22]\]Case-controlEgyptNS98/10247.8 ± 14.2 (total)50/56ESRD undergoing hemodialysisHypertension-associated (44.9%)\
Diabetes-associated (11.2%)\
Preeclampsia (4%)\
Drug-induced (3%)\
Glomerulonephritis (6.1%)\
Obstructive uropathy (5.1%)\
Atrophic kidney (3%)\
Systemic lupus erythematosus (5.1%)\
Polycystic kidney (2%)\
Combined polycystic kidney and hypertension (1%)\
Combined DM and hypertension (6.1%)\
Amyloidosis and hypertension (1%)\
Idiopathic (7.1%)Rezk et al. \[[@CR23]\]Case-controlEgyptNS178 (83 NT; 95 HT)/ 17847.4 ± 9.3 (case)\
NS (control)NSeGFR (according to K/DOQ1 guidelines)Hypertension-associated (53.4%)\
NS (46.6%)Abdallah et al. \[[@CR26]\]Case-controlEgyptNS139/50NS48.2/NSESRD undergoing hemodialysisNSElshamaa et al. \[[@CR25]\]Case-controlEgyptNS78/709.14 ± 7.59 (CT); 10.62 ± 3.49 (MHT) (case)\
10.7 ± 4.51 (control)51/57eGFR (according to K/DOQ1 guidelines):\
*Undergoing CT* GFR (range, 15--29 ml/min/1.73m^2^) *Undergoing MHD* GFR (range, 5--15 ml/min/1.73m^2^)Advanced CKD with the following aetiology:\
Renal hypoplasia/dysplasia (20.5%)\
Obstructive uropathies (17.9%)\
Neurogenic bladder (7.7%)\
Metabolic (2.6%)\
Hereditary nephropathies (21.8%)\
Glomerulopathy (2.6%)\
Idiopathic (26.9%)Elhelbawy et al. \[[@CR24]\]Case-controlEgyptNS70/3060.2 ± 9.4 (case)\
58.9 ± 10.7 (control)61.4/63.3ESRD undergoing hemodialysisNS*ACR* albumin/creatinine ratio, *CKD* chronic kidney disease, *CKD-EPI* Chronic Kidney Disease Epidemiology Collaboration, *CT* conservative treatment, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *ESRD* end-stage renal disease, *HT* hypertensive, *K/DOQI* NKF Kidney Disease Outcomes Quality Initiative, *MDRD* Modification of Diet in Renal Disease, *MHD* maintenance hemodialysis, *MRF* moderate renal failure, *NS* not specified, *NT* normotensive, *PCR* polymerase chain reaction, *RFLP* restriction fragment length polymorphism, *SRF* severe renal failure, *SSA* sub-Saharan Africa

Table [2](#Tab2){ref-type="table"} summarizes the polymorphisms investigated in the included studies. Thirty different polymorphisms (including SNP, indels and repeats) in 11 genes have been studied in various population groups in Africa. Of the polymorphisms investigated by selected studies, only three SNPs of the *APOL1* gene (rs73885319, rs60910145, rs71785313) were studied in more than one population group, which included the Yoruba \[[@CR29]\] and Igbo \[[@CR30]\] tribes of Nigeria and the South African mixed-race population group \[[@CR27]\]. The remaining 27 polymorphisms of the *MYH9*, *apoE, AT1R, eNOS, MTHFR, XPD, XRCC1, renalase, ADIPOQ* and *CCR2* genes were each studied in only one ethnic group. Eight of the included genetic association studies assessed the distribution of allele frequency by formally testing for Hardy-Weinberg equilibrium (HWE), and one study assumed HWE without formal testing \[[@CR21]\]. Of those formally tested, only one polymorphism showed a departure from HWE (*MYH9* rs4821480), and was subsequently removed from further association analysis in that study \[[@CR28]\]. Adjustment for confounders was not consistent across studies, with six studies not providing information on the degree of adjustment or variables accounted for \[[@CR21]--[@CR26]\]. The remaining seven studies all adjusted for at least age and gender \[[@CR18]--[@CR20], [@CR27]--[@CR30]\]. In all studies, the genomic DNA was extracted from whole blood samples and genotyped by methods including TaqMan genotyping assays, polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) and gel-electrophoresis and confirmed by PCR-sequencing.Table 2Polymorphisms investigated in African studiesAuthorGene (chromosome region)PolymorphismMinor allele frequency: case/control (%)Genotyping methodHWEAdjustmentEffect estimate OR/ HR (95% CI)OutcomeTayo et al. \[[@CR29]\]*APOL1* (22q12.3)rs9622363A: 25.86/29.75Custom Fluidigm ™ 96.96 array platform; TaqMan genotyping assay0.788Age\
GenderOR (additive): 0.76 (0.45 to1.31); *p* = 0.875\
OR (dominant): 0.88 (0.47 to 1.66); *p* = 0.999\
OR (recessive): 0.24 (0.05 to 1.29); *p* = 0.377CKDrs73885319A: 44.19/26.581.00OR (additive): 2.29 (1.39 to 3.77); *p* = 0.005\
OR (dominant): 2.59 (1.34 to 5.00); *p* = 0.025\
OR (recessive): 3.85 (1.31 to 11.36); *p* = 0.038rs60910145G: 50.00/30.130.114OR (additive): 2.04 (1.32 to 3.17); *p* = 0.006\
OR (dominant): 2.54 (1.31 to 4.92); *p* = 0.034\
OR (recessive): 3.12 (1.35 to 7.20); *p* = 0.015G2: rs71785313D: 8.62/12.661.00OR (additive): 0.61 (0.29 to 1.31); *p* = 0.701\
OR (dominant): 0.64 (0.29 to 1.40); *p* = 0.816\
OR (recessive): NSG1: rs73885319 and rs6091014544.19/26.92 (A-G haplotype)OR (additive): 2.25 (1.36 to 3.71); *p* = 0.005\
OR (dominant): 2.52 (1.30 to 4.88); *p* = 0.051\
OR (recessive): 3.80 (1.29 to 11.22); *p* = 0.02650.00/69.87 (G-T haplotype)OR (additive): 0.49 (0.32 to 0.76); p = 0.005\
OR (dominant): 0.32 (0.14 to 0.73); *p* = 0.018\
OR (recessive): 0.40 (0.21 to 0.77); *p* = 0.031*MYH9* (22q12.3)rs11912763A: 38.51/27.221.00OR (additive): 1.68 (1.02 to 2.76); *p* = 0.197\
OR (dominant): 2.03 (1.06 to 3.87); *p* = 0.183\
OR (recessive): 1.70 (0.58 to 4.94); *p* = 0.872rs2032487T: 18.39/26.280.770OR (additive): 0.68 (0.40 to 1.16); *p* = 0.580\
OR (dominant): 0.64 (0.33 to 1.23); *p* = 0.645\
OR (recessive): 0.55 (0.14 to 2.22); *p* = 0.934rs4821481T: 18.39/26.580.777OR (additive): 0.66 (0.39 to 1.13); *p* = 0.532\
OR (dominant): 0.61 (0.32 to 1.18); *p* = 0.583\
OR (recessive): 0.55 (0.14 to 2.24); *p* = 0.940rs5750248C: 25.86/36.081.00OR (additive): 0.61 (0.37 to 0.99); *p* = 0.225\
OR (dominant): 0.56 (0.29 to 1.05); *p* = 0.354\
OR (recessive): 0.46 (0.15 to 1.41); *p* = 0.627rs5750250A: 26.16/37.970.635OR (additive): 0.56 (0.34 to 0.94); *p* = 0.141\
OR (dominant): 0.51 (0.27 to 0.97); *p* = 0.208\
OR (recessive): 0.44 (0.14 to 1.38); *p* = 0.576Ulasi et al. \[[@CR30]\]*APOL1* (22q12.3)G1: rs73885319 and rs60910145\
G2: rs7178531359/30\
20/23PCR-sequencing; PCR-RFLPNSAge\
Gender\
BMI\
HIVOR: 4.8 (1.6 to 14.9); p = 5.1E-03CKDMatsha et al. \[[@CR28]\]*MYH9* (22q12.3)rs5756152G: 12.4 (overall)PCR-sequencing; TaqMan genotyping assay\> 0.999Age\
Gender\
Diabetes\
ACROR (additive): − 2.3 (− 5.6 to 0.9); *p* = 0.16\
OR (additive): 1.91 (− 1.32 to 5.15); *p* = 0.25\
OR (additive): 1.83 (− 1.23 to 4.89); *p* = 0.24\
OR (additive): − 1.6 (− 18.9 to 15.6); *p* = 0.85Serum creatinine\
eGFR(MDRD)\
eGFR (CKD-EPI)\
ACRrs4821480T: 30.3 (overall)0.053NSrs12107A: 22.2 (overall)0.908OR (additive): 0.4 (− 2.2 to 2.9); *p* = 0.78\
OR (additive): − 0.07 (− 2.61 to 2.46); *p* = 0.95\
OR (additive): 0.13 (− 2.27 to 2.54); *p* = 0.91\
OR (additive): 1.0 (− 12.6 to 14.5); *p* = 0.90Serum creatinine\
eGFR(MDRD)\
eGFR (CKD-EPI)\
ACRMatsha et al. \[[@CR27]\]*APOL1*\
(22q12.3)rs73885319G: 3.6 (overall)PCR-sequencing;\
TaqMan\
genotyping assay0.150Age\
Gender\
Diabetes\
HypertensionOR (additive): -0.018 (-0.069 to 0.0034); p=0.503\
OR (dominant): -0.026 (-0.080 to 0.028); p=0.341\
OR (recessive): 0.191 (-0.094 to 0.478); p=0.189Serum creatinineOR (additive): 0.99 (-4.42 to 6.40); p=0.720\
OR (dominant): 1.75 (-9.93 to 7.44); p=0.546\
OR (recessive): -18.54 (-48.59 to 11.51); p=0.227eGFR(MDRD)OR (additive): 2.07 (-2.40 to 6.55); p=0.364\
OR (dominant): 2.96 (-1.74 to 7.66); p=0.217\
OR (recessive): -18.90 (-43.76 to 5.96); p=0.136eGFR (CKD-EPI)OR (additive): 0.76 (0.27 to 2.16); p=0.601\
OR (dominant): 0.56 (0.18 to 1.79); p=0.307\
OR (recessive): 23.47 (0.92 to 599.29); p=0.074CKD (MDRD)OR (additive): 1.08 (0.38 to 3.03); p=0.887\
OR (dominant): 0.81 (0.26 to 2.54); p=0.720\
OR (recessive): 42.72 (1.22 to ∞); p=0.047CKD (CKD-EPI)OR (additive): -0.126 (-0.446 to 0.195); p=0.442\
OR (dominant): -0.096 (-0.436 to 0.245); p=0.583\
OR (recessive): -1.02 (-2.62 to 0.57); p=0.210ACRrs60919145G: 3.4 (overall)0.127OR (additive): -0.020 (-0.072 to 0.033); p=0.466\
OR (dominant): -0.029 (-0.084 to 0.026); p=0.307\
OR (recessive): 0.192 (-0.094 to 0.478); p=0.289Serum creatinineOR (additive): 1.26 (-4.27 to 6.79); p=0.656\
OR (dominant): 2.09 (-3.73 to 7.91); p=0.482\
OR (recessive): -18.54 (-48.59 to 11.51); p=0.227eGFR(MDRD)OR (additive): 2.28 (-2.29 to 6.86); p=0.328\
OR (dominant): 3.24 (-1.57 to 8.06); p=0.187\
OR (recessive): -18.90 (-43.76 to 5.96); p=0.136eGFR (CKD-EPI)OR (additive): 0.80 (0.28 to 2.27); p=0.665\
OR (dominant): 0.59 (0.18 to 1.89); p=0.350\
OR (recessive): 23.47 (0.92 to 599.29); p=0.074CKD (MDRD)OR (additive): 1.12 (0.39 to 3.16); p=0.836\
OR (dominant): 0.84 (0.27 to 2.65); p=0.767\
OR (recessive): 42.72 (1.22 to ∞); p=0.047CKD (CKD-EPI)OR (additive): -0.178 (-0.504 to 0.147); p=0.283\
OR (dominant): -0.154 (-0.502 to 0.193); p=0.384\
OR (recessive): -1.02 (-2.62 to 0.57); p=0.210ACRrs71785313Del: 5.8 (overall)0.420OR (additive): 0.019 (-0.022 to 0.060); p=0.367\
OR (dominant): -0.020 (-0.024 to 0.064); p=0.382\
OR (recessive): 0.038 (-0.144 to 0.219); p=0.684Serum creatinineOR (additive): -2.38 (-6.68 to 1.93); p=0.323\
OR (dominant): -2.35 (-6.99 to 2.30); p=0.323\
OR (recessive): -7.16 (-26.19 to 11.87); p=0.461eGFR(MDRD)OR (additive): -2.91 (-6.46 to 0.65); p=0.110\
OR (dominant): -3.03 (-6.88 to 0.81); p=0.123\
OR (recessive): -5.99 (-21.74 to 9.76); p=0.456eGFR (CKD-EPI)OR (additive): 0.86 (0.39 to 1.93); p=0.712\
OR (dominant): 0.91 (0.38 to 2.14); p=0.823\
OR (recessive): 0.0CKD (MDRD)OR (additive): 1.00 (0.42 to 2.34); p=0.993\
OR (dominant): 1.07 (0.43 to 2.66); p=0.890\
OR (recessive): 0.0CKD (CKD-EPI)OR (additive): 0.035 (-0.207 to 0.277); p=0.777\
OR (dominant): 0.050 (-0.214 to 0.314); p=0.710\
OR (recessive): -1.123 (-1.134 to 0.888); p=0.811ACRLahrach et al. \[[@CR21]\]*apoE*\
(19q13.32)e2 (rs7412-T,\
rs429358-T)3.0/6.0PCR-sequencing;\
gelelectrophoresisNSNoneOR (NS): 0.473 (0.181 to 1.235); p=0.093ESRDe3 (rs7412-C,\
rs429358-T73.0/82.0\
(Reference)Reference groupe4 (rs7412-C,\
rs429358-C)24.0/12.0OR (NS): 0.491 (0.277 to 0.870); p=0.009 (UA)Hanna et al. \[[@CR19]\]*AT1R* (3q24)A1166CC: 86.0/83.0PCR-RFLPNSAge\
GenderHR (NS): 1.254 (0.658 to 2.389); p=0.491ESRDKerkeni et al. \[[@CR20]\]*eNOS*\
(7q36.1)G894T (exon7)T: 27.0/22.1PCR-RFLPSatisfied\
HWE (p-value\
NS)Age\
Gender\
Smoking\
Hypertension\
Dyslipidaemia\
Cholesterol\
Homocysteine\
MTHFR C677T\
eNOS G894TEE not reported; p=0.028 (difference in allele\
frequency)CKDElshamaa et al. \[[@CR18]\]*eNOS*\
(7q36.1)4a (intron4)CT and MHD/controls: 32.8 and 33.7/22.7\
CT and MHD/controls: 67.2 and 66.3/78.3PCR-sequencing;\
gelelectrophoresisSatisfied\
HWE (p-value\
NE)Age\
Hypertension\
SBP\
DBP\
Serum NOEE not reported; p\<0.05 (patient groups vs control)Advanced CKD\
(ESRD)Radwan et al. \[[@CR22]\]*XPD* (9)Asp312AsnAsn: 35.0/36.0PCR-RFLPSatisfied\
HWE (p-value\
NE)NSOR (NS): 0.93 (0.53 to 1.64); p=0.93ESRDLys751GlnGln: 37.0/37.0OR (NS): 0.98 (0.55 to 1.74); p=0.94*XRCC1* (NS)Arg399GlnGln: 34.0/19.0OR (NS): 2.48 (1.36 to 4.52); p=0.002Rezk et al. \[[@CR23]\]*Renalase*\
(10q23.21)rs2296545C: 28.7/16.3\
C: 29.4/16.3\
(hypertensive\
CKD/controls)PCR-RFLPSatisfied\
HWE (p-value\
NE)NSOR: 2.14 (1.07 to 4.26); p=0.04\
OR: 2.10 (1.07 to 4.26); p=0.041 (hypertensive\
CKD/controls)CKD\
Hypertensive CKDAbdallah et al. \[[@CR26]\]*Renalase*\
(10q23.21)rs2576178G: 56/16PCR-sequencing;\
gelelectrophoresisNSNSOR: 7.188 (3.5 to 14.7); p\<0.05ESRDrs10887800G: 26/12OR: 12.3 (5.6 to 27.1); p\<0.05Elshamaa et al. \[[@CR25]\]*ADIPOQ*\
(3q27.3)rs1501299G\>T;T: 18.6/10.7\
T (CT/MHD):\
15.6/20.7PCR-sequencing;\
gelelectrophoresisSatisfied\
HWE (p-value\
NE)NSp=0.04 (TT genotype distribution between cases and controls)Advanced CKD\
(ESRD)rs2241766T\>GG: 0.0/0.0\
G (CT/MHD):\
0.0/0.0Elhelbawy et al. \[[@CR24]\]*CCR2*\
(3q21.31)G190AG: 75.7/90.0\
A: 24.3/10.0PCR-RFLPNSNSOR: 2.8 (1.40 to 5.51); p\<0.05\
OR: 4.1 (1.27 to 13.03); p\<0.05\
OR: 2.9 (1.14 to 7.3); p\<0.05CKD*ACR* albumin/creatinine ratio, *BMI* body mass index, *CKD* chronic kidney disease, *CKD-EPI* Chronic Kidney Disease Epidemiology Collaboration, *CRF* chronic renal failure, *CT* conservative treatment, *DBP* diastolic blood pressure, *EE* effect estimate, *eGFR* estimated glomerular filtration rate, *ESRD* end-stage renal disease, *HIV* human immunodeficiency virus, *HR* hazard ratio, *HWE* Hardy--Weinberg equilibrium, *MAF* minor allele frequency, *MDRD* Modification of Diet in Renal Disease, *MHD* maintenance hemodialysis, *NO* nitric oxide, *NS* not specified, *OR* odds ratio, *SBP* systolic blood pressure, *UA* unadjusted

Association of genetic markers with CKD and related traits {#Sec10}
----------------------------------------------------------

According to the studies included in this review, some SNP's investigated in the *MYH9* \[[@CR28]\], *AT1R* \[[@CR19]\], and *MTHFR* \[[@CR20]\] genes failed to predict prevalent CKD, ESRD or related traits (serum creatinine, eGFR and ACR), while variants in the *APOL1* \[[@CR27], [@CR29], [@CR30]\], *apoE* \[[@CR21]\], *eNOS* \[[@CR18], [@CR20]\], *XPD* \[[@CR22]\], *XRCC1* \[[@CR22]\], *renalase* \[[@CR23], [@CR26]\], *ADIPOQ* \[[@CR31]\] and *CCR2* \[[@CR24]\] genes were associated with either prevalent CKD or progression of CKD, ESRD, or other surrogate measures of renal function.

The majority of CKD-associated polymorphisms were conducted in single studies. In a Moroccan population, the e4 allele and the E3E4 genotype of the *apoE* gene demonstrated a significant association with ESRD (OR = 0.491; *p* = 0.009 and OR = 0.316, *p* \< 0.001, e4 and E3E4, respectively) \[[@CR21]\]. However, this association was unadjusted for any potential confounder effects. Both Kerkeni et al. \[[@CR20]\] and Elshamaa et al. \[[@CR18]\] conducted genetic association studies on SNPs in the *eNOS* gene, adjusting for potential confounders, albeit different population groups and different SNPs. According to Kerkeni et al. \[[@CR20]\], the *eNOS* SNP found in exon 7 (G894 T) was an independent risk factor of severity of CKD (*p* = 0.01) in Tunisian adults. Similarly, Elshamaa et al. \[[@CR18]\] found the a-allele in the *eNOS* (intron 4) gene to predict ESRD in Egyptian children (*p* \< 0.05) \[[@CR18]\]. Radwan et al. \[[@CR22]\] investigated three polymorphisms in the DNA repair genes (*XPD* and *XRCC1*) and found that patients with *XRCC1--399 Arg/Gln* genotype had a significantly higher risk of developing ESRD (OR: 2.48; 95% CI: 1.36--4.52). Furthermore, the haplotypes containing *XRCC1--399 Arg/Gln* and *XPD-312 Asp/Asn* as well as *XRCC1--399 Arg/Gln* and *XPD-751 Lys/Gln* were significantly associated with the development of ESRD (OR: 8.35, 95%CI: 1.94--35.85, *p* = 0.004 and OR: 9.22, 95%CI: 2.14--39.71, *p* = 0.003, respectively). Two studies, both in Egyptian populations, investigated polymorphisms of the renalase gene \[[@CR23], [@CR26]\]. Rezk et al. \[[@CR23]\] found that patients with the CC genotype and carriers of C allele of the rs2296545 renalase gene were significantly more likely to have prevalent CKD (CC genotype; OR: 4.84, 95%CI: 1.28--18.2, *p* = 0.02 and C-carrier; OR: 2.14, 95%CI: 1.07--4.26, *p* = 0.04). Abdallah et al. \[[@CR26]\], conversely found that carriers of the G allele of the rs2576178 and rs10887800 *renalase* gene were associated with increased risk of developing ESRD (OR: 7.188, 95%CI: 3.5--14.7, *p* \< 0.05 and OR: 12.3, 95%CI: 5.6--27.1; *p \<* 0.05). However, in both studies no adjustments were made for potential confounders. ADIPOQ+276G \> T was also investigated for association with ESRD in Egyptian children \[[@CR31]\]. This study suggested that the +276G \> T allele may indirectly contribute to CKD susceptibility by increasing adiponectin levels (p = 0.04). Elhelbawy et al. \[[@CR24]\] found a significant association between *CCR2*--641 and chronic renal failure, particularly the AG genotype (OR = 2.8, 95% CI = 1.40--5.51), combined AG and GG genotypes (OR = 4.1, 95% CI = 1.27--13.03) and A allele (OR = 2.9, 95% CI = 1.14--7.3).

As seen in Table [2](#Tab2){ref-type="table"}, only polymorphisms in the *APOL1* gene were investigated in more than one ethnic group, with the observed association similar in at least two population groups. Indeed, according to the study conducted in the Yoruba tribe of Nigeria \[[@CR29]\], two single *APOL1* SNPs (rs73885319 and rs60910145) were significantly associated with CKD under all genetic models, with the largest effect under the recessive model (OR: 3.85 and 3.12 for rs73885319, and rs60910145, respectively). Furthermore, due to the linkage disequilibrium (D-prime = 1.00, *r*^2^ = 0.82) between the two SNPs, adjusting for either SNP resulted in no association for the other SNP. Similarly, albeit a different population (mixed-race South Africans), Matsha et al. \[[@CR27]\] found the same two single SNPs (rs73885319 and rs60910145) to be associated with prevalent CKD, however only under the recessive model (*p* = 0.047) (as measured by the CKD-EPI eGFR equation), even after adjusting for multiple confounders. The study did not observe an association between these single *APOL1* SNPs and any of the other surrogate measures of kidney function. Tayo et al. \[[@CR29]\] also investigated the adjusted association of *APOL1* haplotypes, namely the G-A-G haplotype (rs9622363--rs73885319--rs60910145) and the G1 haplotype (rs73885319 and rs60910145) and found both to be significantly associated with CKD under all models of genetic association (G-A-G, ORs: 2.26; *p* = 0.005, OR: 2.54; *p* = 0.023 and OR: 3.79; *p* = 0.041 for the additive, dominant and recessive modes; G1, OR: 2.25; *p* = 0.006, OR: 2.52; *p* = 0.025 and OR: 3.80; p = 0.041 for the additive, dominant and recessive modes). Ulasi et al. \[[@CR30]\] also conducted a study on the *APOL1* G1 haplotype (rs73885319 and rs60910145) and G2 (rs71785313) (Wt:G1 or Wt:G2; G1:G1 or G1:G2 or G2:G2) in the Igbo tribe of Nigeria. This study found no significant effect of the Wt:G1 or Wt:G2 one-copy, but observed a high association between *APOL1* two-risk alleles (G1:G1 or G1:G2 or G2:G2) and CKD (OR: 4.8; *p* = 5.1E-03), even after adjusting for various confounders.

Discussion {#Sec11}
==========

To the best of our knowledge, this is the first comprehensive report of the current evidence on genetic polymorphisms associated with renal disease amongst populations in Africa. This review highlights the lack of genetic association studies conducted within the borders of Africa, despite the known genetic link to CKD and the genetic diversity in Africa.

All the studies included in this review used the candidate gene approach, and amongst these, only *MYH9* polymorphisms has been previously investigated by GWAS and showed directional association with CKD in populations elsewhere \[[@CR10]\]. Indeed, multiple *MYH9* SNPs have been identified as powerful predictors of non-diabetic kidney disease in African Americans \[[@CR32]\], Hispanic-Americans \[[@CR33]\], and individuals of European ancestry \[[@CR34]\]. However, from this review we found no evidence for the associative role of *MYH9* polymorphisms in non-diabetic CKD patients in Africa, as all eight SNPs investigated in populations from Nigeria and South Africa failed to predict prevalent CKD or any other surrogate measure of kidney function \[[@CR28], [@CR29]\]. Differences in linkage disequilibrium structure might however explain the lack of genetic association in studies conducted in these African populations. Indeed, previous studies have shown that the G1 and G2 risk variants of the *APOL1* gene are in strong linkage disequilibrium with variants in *MYH9.* Indeed, most of the association previously attributed to *MYH9* variants or haplotypes with CKD could be explained by their genetic linkage with *APOL1* polymorphisms in populations of African ancestry residing outside the African continent \[[@CR35], [@CR36]\]. In contrast, the studies included in this review instead observed independent association between four SNPs of the *APOL1* gene and with either prevalent CKD, serum creatinine, eGFR or ACR in the included studies \[[@CR27], [@CR29], [@CR30]\]. This strong association between *APOL1* polymorphisms and non-diabetic kidney disease found in studies in this review have been replicated in several studies \[[@CR37]--[@CR45]\] since the initial findings reported in African Americans \[[@CR35], [@CR36]\]. In addition, as reported in all the above mentioned studies, the risk is mostly conferred by the presence of two copies of the risk alleles, that is, homozygous or compound heterozygous compared to no or one *APOL1* risk variant \[[@CR35], [@CR36]\]. It would therefore be of great interest if larger population studies are conducted to ascertain the kidney disease-*APOL1* association across African population groups.

Currently, the role of the polymorphisms in the *apoE* \[[@CR21]\], *eNOS* \[[@CR18], [@CR20]\], *XPD* \[[@CR22]\], *XRCC1* \[[@CR22]\], *renalase* \[[@CR23], [@CR26]\], *ADIPOQ* \[[@CR31]\] and *CCR2* \[[@CR24]\] genes in the aetiology of CKD remains controversial and further larger studies should be conducted to confirm these results in population groups within Africa. Certainly, various polymorphisms have been associated, both directly and indirectly, with increased CKD risk in certain populations and decreased CKD risk in others or alternatively have no convincing association. This is true for the polymorphisms investigated in the current review. For example, Lahrach et al. \[[@CR21]\] showed that the e4 allele and the E3E4 genotype of the *apoE* gene demonstrated a strong association with ESRD, similar to a study conducted in a Swedish population \[[@CR46]\]. However, a study conducted in African Americans and European Americans showed an opposite effect, with the e4 allele being associated with decreased risk of ESRD progression and decreased risk of prevalent ESRD \[[@CR47]\], with no association found between the e4 allele and CKD in Asian populations \[[@CR48]\]. The genetic link between *eNOS* (4a; intron4) and ESRD \[[@CR18]\] and CKD severity (G894 T; exon7) \[[@CR20]\] have also been studied in two African populations, and in both studies, as in various other studies \[[@CR49]--[@CR51]\], the polymorphisms under investigation were found to be significantly associated with kidney disease. However, this association between polymorphisms of *eNOS* and kidney disease is not fully elucidated, as the direction and magnitude have been found to differ by population and even within the same population. For example, Bellini et al. \[[@CR52]\] demonstrated a strong association between *eNOS* 4a polymorphism and ESRD risk in a Brazilian population, while Marson et al. \[[@CR53]\] found no significant correlation between *eNOS* 4a polymorphism and ESRD risk in a similar Brazilian population group. The association between DNA repair genes (XPD and XRCC1) and kidney disease is not commonly investigated, and with the exception of the study reviewed in this publication \[[@CR22]\], has only been investigated previously in a Turkish population \[[@CR54]\]. Both studies showed an association between DNA repair gene polymorphisms and ESRD development. However, the effect estimates amongst the African population were higher than that reported in the Turkish population. From the included studies, it is evident that investigating regional differences in the relationship between genes and CKD risk within Africa has relevance, considering the genetic diversity among ethnic population groups in the continent \[[@CR55]\].

Our study has some limitations, which include the small number of existing studies, which precluded statistical analysis by means of meta-analysis. Furthermore, as a result of existing genetic association studies not always reporting on key methodological information that includes testing the HWE, the sample size/power calculations, clear description of controls, consideration and correction for population stratification, as well as the levels of adjustment, it is difficult to draw definitive inferences from these studies. In addition, the sample size of the included studies was much smaller than other studies conducted outside of Africa, thus as a result it is possible that with larger sample sizes, additional previously proposed candidate genes may have reached statistical significance. Indeed, with the largest included study comprising 859 participants \[[@CR27]\], it is highly likely that most existing studies on the genetics of kidney disease in Africa have been underpowered to replicate existing loci or estimate effects with precision. Furthermore, the majority of included studies were conducted in Egyptian populations, thus not covering all the scope of genetic variations that exist on the African continent. The age range, which varied from approximately 9--60 years, and the range of covariates included in adjustment of the estimates of association also differed substantially across studies and could possibly affect between-studies comparisons. In addition, since we had no access to individual participant data, refined analyses and accounting for potential confounders and other types of bias, could not be executed. However, despite the shortcomings of this review, the strength resides in the fact that, according to our knowledge, this is the first study to systematically and comprehensively review the existing data on genetic association studies of CKD in the context of Africa.

Conclusion {#Sec12}
==========

The putative genetic risk factors that have emerged from current data represent the most promising kidney disease susceptibility genes described to date in populations within Africa. However, larger-scale genetic association studies are needed to further expand our knowledge of the underlying genetic mechanisms of kidney disease among populations within Africa.
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ACR

:   Albumin to creatinine ratio

*ADIPOQ*

:   Gene encoding adiponectin

*apoE*

:   Gene encoding apolipoprotein E

*APOL1*

:   Apolipoprotein L1

*AT1R*

:   Gene encoding angiotensin II receptor type 1

BMI

:   Body mass index

*CCR2*

:   Gene encoding C-C chemokine receptor type 2

CKD

:   Chronic kidney disease

CKD-EPI

:   Chronic Kidney Disease Epidemiology Collaboration

CRF

:   Chronic renal failure

CT

:   Conservative treatment

DBP

:   Diastolic blood pressure

DM

:   Diabetes mellitus

EE

:   Effect estimate

eGFR

:   Estimated glomerular filtration rate

*eNOS*

:   Gene encoding endothelial nitric oxide synthase

ESRD

:   End-stage renal disease

GWAS

:   Genome-wide association studies

HIV

:   Human immunodeficiency virus

HR

:   Hazard ratio

HT

:   Hypertensive

HWE

:   Hardy-Weinberg equilibrium

K/DOQI

:   NKF Kidney Disease Outcomes Quality Initiative

MAF

:   Minor allele frequency

MDRD

:   Modification of Diet in Renal Disease

MeSH

:   Medical Subject Headings

MHD

:   Maintenance hemodialysis

MRF

:   Moderate renal failure

*MTHFR*

:   Gene encoding Methylene tetrahydrofolate reductase

*MYH9*

:   Gene encoding myosin, heavy chain 9

NO

:   Nitric oxide

NS

:   Not specified

NT

:   Normotensive

OR

:   Odds ratio

PCR-RFLP

:   Polymerase chain reaction restriction fragment length polymorphism

SAMRC

:   South African Medical Research Council

SBP

:   Systolic blood pressure

SNP

:   Single nucleotide polymorphisms

SRF

:   Severe renal failure

SSA

:   Sub-Saharan Africa

UA

:   Unadjusted

*XPD*

:   *G*ene encoding xeroderma pigmentosum group D

*XRCC1*

:   Gene encoding X-ray repair cross-complementing protein 1
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